News & Updates

Back to All News
Get Care

The Lankenau Institute for Medical Research (LIMR) to host the 4th International Conference on Immunochemotherapy on April 16-17

April 16, 2015 Research News

When: Thursday, April 16 and Friday, April 17; News media is invited to attend the presentation by George Prendergast, PhD, President of the Lankenau Institute for Medical Research (LIMR), on “’IDO pathways” on Friday, April 17 from 11:30 am–Noon.

What: The 4th International Conference on Immunochemotherapy, hosted this year by the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, will bring together leading researchers in the quest to improve cancer therapy by using a patient’s own immune system.

Who: This event is being co-chaired by LIMR President George Prendergast, PhD, along with fellow pioneers in the field of immunochemotherapy Guido Kroemer, MD, PhD, and Laurence Zitvogel, MD, PhD, of the Gustave Roussy Cancer Center in Paris, and Jeffrey Weber, MD, PhD, of the Moffitt Cancer Center in Tampa. In addition, the two-day event will feature presentations by researchers from major cancer centers and research institutes across the globe.

Why: Dr. Prendergast will discuss research that began more than 10 years ago at LIMR on so-called “IDO1 inhibitors.” These drugs target an enzyme that tumors “turn on” to suppress the immune system—the research that began at LIMR has since been acquired by several other major pharmaceutical companies… if and when these IDO inhibitors offer a cure for cancer, Philadelphia will be a part of that story.

Where: The Lankenau Institute for Medical Research (LIMR), 100 East Lancaster Avenue, Wynnewood, PA 19096

About Lankenau Institute for Medical Research

Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.